CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

07 ноя 2022 08:03:37 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

25 окт 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

29 сен 2022 11:18:17 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

09 сен 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

24 авг 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

09 авг 2022 16:26:30 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

26 июл 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

12 июл 2022 06:00:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

17 май 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

10 май 2022 16:11:56 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

25 апр 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

16 мар 2022 16:20:58 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

11 мар 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

08 мар 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

03 мар 2022 09:20:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

02 мар 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

24 фев 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

17 фев 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

07 фев 2022 08:03:00 Источник Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

03 фев 2022 08:03:00 Источник Nasdaq GlobeNewswire